[1] |
Aziz M,Aziz H,Waheed Y,et al.Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients[J].Viral Immunol,2018,31(9):632-638.
|
[2] |
Zeuzem S,Gane E,Liaw YF,et al.Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B[J].J Hepatol,2009,51(1):11-20.
|
[3] |
Martens PJ,Gysemans C,Verstuyf A,et al.Vitamin D′s Effect on Immune Function[J].Nutrients,2020,12(5):1248.
|
[4] |
Kim GA,Lim YS,Han S,et al.High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J].Gut,2018,67(5):945-952.
|
[5] |
Chang Y,Choe WH,Sinn DH,et al.Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus(HBV)e Antigen-Positive Chronic HBV Genotype C Infection:A Nationwide,Multicenter,Retrospective Study[J].J Infect Dis,2017,216(11):1407-1414.
|
[6] |
张原青,彭利军,曹忆嵘,等.慢性乙型肝炎肝硬化患者发生肝细胞癌的危险因素分析[J].中华肝脏病杂志,2015(7):512-516.
|
[7] |
Tang A,Hallouch O,Chernyak V,et al.Epidemiology of hepatocellular carcinoma:target population for surveillance and diagnosis[J].Abdom Radiol(NY),2018,43(1):13-25.
|
[8] |
王贵强,段钟平,王福生,等.慢性乙型肝炎防治指南(2019年版)[J].实用肝脏病杂志,2020,23(1):9-32.
|
[9] |
Cho JY,Sohn W,Sinn DH,et al.Long-term real-world entecavir therapy in treatment-nave hepatitis B patients:baseline hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response[J].Korean J Intern Med,2017,32(4):636-646.
|
[10] |
Dobson R,Giovannoni G.Multiple sclerosis-a review[J].Eur J Neurol,2019,26(1):27-40.
|
[14] |
李冰,黄辉红,江自成,等.血清维生素D水平对慢性乙型肝炎患者抗病毒疗效的影响[J].肝脏,2018,23(10):895-897.
|
[11] |
Ye B,Liu X,Li X,et al.T-cell exhaustion in chronic hepatitis B infection:current knowledge and clinical significance[J].Cell Death Dis,2015,6(3):e1694.
|
[12] |
Li TY,Yang Y,Zh ou G,et al.Immune suppression in chronic hepatitis B infection associated liver disease:A review[J].World J Gastroenterol,2019,25(27):3527-3537.
|
[13] |
He LJ,Zhang HP,Li HJ,et al.Effect of Serum Vitamin D Levels on Cellular Immunity and Antiviral Effects in Chronic Hepatitis B Patients[J].Clin Lab,2016,62(10):1933-1939.
|
[15] |
Gal-Tanamy M,Bachmetov L,Ravid A,et al.Vitamin D:an innate antiviral agent suppressing hepatitis C virus in human hepatocytes[J].Hepatology,2011,54(5):1570-1579.
|
[16] |
Matsumura T,Kato T,Sugiyama N,et al.25-Hydroxyvitamin D3suppresses hepatitis C virus production[J].Hepatology,2012,56(4):1231-1239.
|
[17] |
Bi Y,Zhang W,Sun J,et al.Therapeutic and immune function improvement of vitamin D combined with IFN-α on mouse with hepatitis B infection[J].Int J Immunopathol Pharmacol,2018,32:2058738418775250.
|
[18] |
Sheppard-Law S,Zablotska-Manos I,Kermeen M,et al.Factors associated with non-adherence to HBV antiviral therapy[J].Antivir Ther,2018,23(5):425-433.
|